Kiniksa Pharmaceuticals (NASDAQ:KNSA) Rating Reiterated by Wedbush

Kiniksa Pharmaceuticals (NASDAQ:KNSA)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research report issued to clients and investors on Tuesday, RTT News reports. They presently have a $30.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 67.97% from the stock’s current price.

Separately, TheStreet raised shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Thursday, February 29th.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA opened at $17.86 on Tuesday. The firm has a 50-day simple moving average of $19.36 and a two-hundred day simple moving average of $18.00. The stock has a market cap of $1.26 billion, a PE ratio of 99.23 and a beta of 0.27. Kiniksa Pharmaceuticals has a 1-year low of $10.65 and a 1-year high of $22.09.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 23rd. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.11). Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. The company had revenue of $79.90 million during the quarter, compared to analyst estimates of $76.97 million. During the same quarter last year, the business posted ($0.18) EPS. The firm’s revenue for the quarter was up 65.4% on a year-over-year basis. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals will post -0.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Michael R. Megna sold 5,126 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the transaction, the chief accounting officer now owns 17,588 shares of the company’s stock, valued at $383,242.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Sanj K. Patel sold 5,582 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $21.00, for a total transaction of $117,222.00. Following the transaction, the chief executive officer now owns 65,012 shares in the company, valued at approximately $1,365,252. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Michael R. Megna sold 5,126 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the sale, the chief accounting officer now owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The disclosure for this sale can be found here. Insiders sold 33,109 shares of company stock worth $709,929 over the last 90 days. 54.23% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. IFP Advisors Inc purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth about $65,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Kiniksa Pharmaceuticals by 349.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock valued at $72,000 after purchasing an additional 3,186 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $176,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth approximately $213,000. Finally, QRG Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth $249,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.